Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.
Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments.
Methotrexate was granted FDA approval on 7 December 1953.
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma. It is also used in the maintenance of acute lymphocytic leukemia. Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00002552
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 280
- Registration Number
- NCT00002547
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma
- Conditions
- Interventions
- Biological: bleomycin sulfateBiological: filgrastimDrug: cyclophosphamideDrug: cytarabineDrug: doxorubicin hydrochlorideDrug: etoposideDrug: leucovorin calciumDrug: methotrexateDrug: prednisoneDrug: trimethoprim-sulfamethoxazoleDrug: vincristine sulfateRadiation: radiation therapyDrug: Intrathecal cytarabine
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 52
- Registration Number
- NCT00002571
- Locations
- 🇺🇸
MBCCOP - University of South Alabama, Mobile, Alabama, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2010-02-24
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 19
- Registration Number
- NCT00003187
- Locations
- 🇺🇸
University of South Carolina School of Medicine, Columbia, South Carolina, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- United Kingdom Children's Cancer Study Group
- Target Recruit Count
- 100
- Registration Number
- NCT00003423
- Locations
- 🇬🇧
Hospital for Sick Children NHS Trust, London, England, United Kingdom
Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
- Conditions
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2012-03-06
- Target Recruit Count
- 73
- Registration Number
- NCT00003640
- Locations
- 🇮🇹
San Raffaele Hospital, Rome, Italy
Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT00002578
- Locations
- 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 163
- Registration Number
- NCT00003700
- Locations
- 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2004-05-19
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 36
- Registration Number
- NCT00082797
- Locations
- 🇺🇸
Galesburg Cottage Hospital, Galesburg, Illinois, United States
🇺🇸Rush-Copley Cancer Care Center, Aurora, Illinois, United States
🇺🇸Hubert H. Humphrey Cancer Center at North Memorial Medical Center, Robbinsdale, Minnesota, United States
Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia
- First Posted Date
- 2004-05-19
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 43
- Registration Number
- NCT00002961
- Locations
- 🇺🇸
Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸Children's Mercy Hospital, Kansas City, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.